SEARCH

SEARCH BY CITATION

References

  • 1
    Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation, 2013;127:e6e245.
  • 2
    Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 2013;34:29493003.
  • 3
    Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol, 2012;60:e44e164.
  • 4
    Boden WE, O'Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 2007;356:15031516.
  • 5
    BARI 2D Study Group, Frye RL, August P et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med, 2009;360:25032515.
  • 6
    Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil, 2009;16:121137.
  • 7
    Riley RF, Don CW, Powell W, Maynard C, Dean LS. Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes, 2011;4:193197.
  • 8
    Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W et al. Guidelines on myocardial revascularization. Eur Heart J, 2010;31:25012555.
  • 9
    Samuels BA, Diamond GA, Mahrer PR, Denton TA. Intensity of antianginal therapy in patients referred for coronary angiography: a comparison of fee-for-service and health maintenance organization therapeutic strategies. Clin Cardiol, 2000;23:165170.
  • 10
    Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA, 2011;305:18821889.
  • 11
    Howard DH, Shen YC. Trends in PCI Volume after Negative Results from the COURAGE Trial. Health Serv Res, 2014;49:153170.
  • 12
    Borden WB, Spertus JA, Mushlin AI, Roe MT, McCoy LA, Redberg RF. Antianginal therapy before percutaneous coronary intervention. Circ Cardiovasc Interv, 2013;6:436443.
  • 13
    Elder DH, Pauriah M, Lang CC et al. Is there a Failure to Optimize theRapy in anGinapEcToris (FORGET) study? QJM, 2010;103:305310.
  • 14
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet, 2008;372:817821.
  • 15
    Ardati AK, Pitt B, Smith DE et al. Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention. Am Heart J, 2013;165:778784.
  • 16
    Poses RM, Krueger JI, Sloman S, Elstein AS. Physicians' judgments of survival after medical management and mortality risk reduction due to revascularization procedures for patients with coronary artery disease. Chest, 2002;122:122133.
  • 17
    Lin GA, Dudley RA, Redberg RF. Cardiologists' use of percutaneous coronary interventions for stable coronary artery disease. Arch Intern Med, 2007;167:16041609.
  • 18
    Debney MT, Fox KF. Rapid access cardiology–a nine year review. QJM, 2012;105:231234.
  • 19
    Department of Health. The NHS Improvement Plan: Putting people at the heart of public services London: The Stationery Office, 2004. Available at: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4084476 (accessed 19 January 2014).
  • 20
    Kim YH, Park DW, Ahn JM et al. Impact of ad hoc percutaneous coronary intervention with drug-eluting stents in angina patients. EuroIntervention, 2013;9:110117.
  • 21
    Kocas C, Abaci O, Oktay V et al. Percutaneous coronary intervention vs. optimal medical therapy - the other side of the coin: medication adherence. J Clin Pharm Ther, 2013;38:476479.
  • 22
    Whittle J, Conigliaro J, Good CB, Kelley ME, Skanderson M. Understanding of the benefits of coronary revascularization procedures among patients who are offered such procedures. Am Heart J, 2007;154:662668.
  • 23
    Davidson PM, Salamonson Y, Rolley J et al. Perception of cardiovascular risk following a percutaneous coronary intervention: a cross sectional study. Int J Nurs Stud, 2011;48:973978.
  • 24
    Hlatky MA, Solomon MD, Shilane D, Leong TK, Brindis R, Go AS. Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention. J Am Coll Cardiol, 2013;61:295301.
  • 25
    Rushworth GF, Cunningham S, Mort A, Rudd I, Leslie SJ. Patient-specific factors relating to medication adherence in a post-percutaneous coronary intervention cohort. Int J Pharm Pract, 2012;20:226237.
  • 26
    Griffo R, Ambrosetti M, Tramarin R et al. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey. Int J Cardiol, 2013;167:13901395.